SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Quality of reporting of adverse events in clinical trials of covid-19 drugs: systematic review
6 references·0 citing·27 second hop
Quality of reporting of adverse events in clinical trials of covid-19 drugs: systematic review (2023)Quality of reporting of adverse events in…CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials (2023)CONSORT Harms 2022 statement,…Adverse Events Reporting Quality of Randomized Controlled Trials of COVID-19 Vaccine Using the CONSORT Criteria for Reporting Harms: A Systematic Review (2022)Adverse Events Reporting Qual…Quality of reporting of harms in randomised controlled trials of pharmacological interventions for rheumatoid arthritis: a systematic review (2017)Quality of reporting of harms…Adverse event methods were heterogeneous and insufficiently reported in randomized trials on persistent depressive disorder (2015)Adverse event methods were he…The Cochrane Collaboration's tool for assessing risk of bias in randomised trials (2011)The Cochrane Collaboration's …Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement (2004)Better Reporting of Harms in …Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study (1997)Burden of Depressive Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of Disease Study 2010 (2013)Effectiveness of metacognitive interventions for mental disorders in adults—A systematic review and meta‐analysis (METACOG) (2018)Assessing the unwanted: A systematic review of instruments used to assess negative effects of psychotherapy (2019)Strengthening the reporting of harms of all interventions in clinical trials (2022)Reporting results of cancer treatment (1981)The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials (2001)The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration (2001)The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement (2007)CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials (2010)CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials (2010)Cochrane Handbook for Systematic Reviews of Interventions (2008)QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies (2011)ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions (2016)RoB 2: a revised tool for assessing risk of bias in randomised trials (2019)CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials (2010)CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials (2010)Recommendations for the Reporting of Harms in Manuscripts on Clinical Trials Assessing Osteoarthritis Drugs: A Consensus Statement from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) (2019)Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a cross-sectional study of RCTs from a Cochrane systematic review (2024)COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries (2021)Reporting quality was suboptimal in a systematic review of randomized controlled trials with adaptive designs (2022)Measuring Health (2006)CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials (2010)SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials (2013)Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration (2024)CONSORT 2025 explanation and elaboration: updated guideline for reporting randomised trials (2025)SPIRIT 2025 explanation and elaboration: updated guideline for protocols of randomised trials (2025)
this work references cited by second hop

References

  • 2011The Cochrane Collaboration's tool for assessing risk of bias in randomised trials33,776 cited
  • 2004Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement1,588 cited
  • 2023CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials276 cited
  • 2015Adverse event methods were heterogeneous and insufficiently reported in randomized trials on persistent depressive disorder45 cited
  • 2017Quality of reporting of harms in randomised controlled trials of pharmacological interventions for rheumatoid arthritis: a systematic review27 cited
  • 2022Adverse Events Reporting Quality of Randomized Controlled Trials of COVID-19 Vaccine Using the CONSORT Criteria for Reporting Harms: A Systematic Review11 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work